Latest Conference Articles

Gautam Jayram, MD, discusses the current indications for immunotherapy agents in the bladder cancer treatment paradigm, as well as immune-related adverse effects to be aware of when treating patients who are receiving these therapies.

Sandip P. Patel, MD, discusses the 2023 Bridging the Gaps in Lung Cancer meeting, expanding on the continued importance of replicating clinical trial approaches in the real-world setting.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Heather Lynn McArthur, MD, MPH, discusses the primary results from the phase 3 KEYNOTE-756 study of neoadjuvant pembrolizumab plus chemotherapy in early-stage, high-risk, estrogen receptor–positive, HER2-negative breast cancer.

Byoung Chul Cho, MD, PhD, discusses key findings from the phase 3 MARIPOSA study of first-line amivantamab plus lazertinib vs osimertinib in EGFR-mutant locally advanced or metastatic non– small cell lung cancer.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Filippo Pietrantonio, MD, discusses the influence of primary results from the phase 3 CodeBreak 300 trial of sotorasib plus panitumumab on KRAS G12C-mutated metastatic colorectal cancer.

Kim N. Chi, MD, FRCPC, discusses data from the updated and final analysis of the phase 3 MAGNITUDE trial in BRCA-positive metastatic castration-resistant prostate cancer.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Nicolas Girard, MD, PhD, discusses primary efficacy results from the phase 3 PAPILLON trial of amivantamab plus chemotherapy in EGFR exon 20 insertion–mutated advanced non–small cell lung cancer.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Lyudmila A. Bazhenova, MD, discusses the 2023 Bridging the Gaps in Lung Cancer meeting, emphasizing the importance of collaborative efforts when approaching gaps in lung cancer care.

Ravi Salgia, MD, PhD, discusses the 2023 Bridging the Gaps in Lung Cancer meeting, highlighting unmet needs that remain regarding treatment-related toxicities that can arise with commonly used agents in patients with lung cancer.

Erminia Massarelli, MD, PhD, MS, discusses clinical gaps in lung cancer care that were highlighted at the 2023 Bridging the Gaps in Lung Cancer meeting, emphasizing the importance of molecular testing in patients with small cell lung cancer and collaborations between health care networks in this treatment arena.

Sandip P. Patel, MD, discusses the 2023 Bridging the Gaps in Lung Cancer meeting, highlighting the similarities and differences between treating lung cancer in community oncology settings vs academic medical center settings.

Elisa Krill-Jackson, MD, highlights the practice-changing effects of fam-trastuzumab deruxtecan-nxki in metastatic, HER2-positive breast cancer, as well as whether there is still a role for trastuzumab emtansine in this setting.

Danielle M. Brander, MD, discusses the primary analysis of the phase 1/2 TRANSCEND CLL 004 trial in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Catherine C. Coombs, MD, discusses the feasibility of switching from treatment with a covalent BTK inhibitor to a BCL-2 inhibitor vs a different covalent BTK inhibitor in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma treated in a real-world setting.

Alexey Danilov, MD, PhD, discusses the investigation of BTK degraders in the treatment of chronic lymphocytic leukemia.

Jennifer A Woyach, MD, discusses the prevalence of recurrent genomic alterations in apoptotic machinery in patients with previously treated chronic lymphocytic leukemia who were refractory to B-cell receptor pathway inhibitors.

Jan Joseph Melenhorst, PhD, discusses the evolving understanding of the use of CAR T-cell therapies in the treatment of patients with chronic lymphocytic leukemia.

Mazyar Shadman, MD, MPH, discusses preliminary long-term findings from the evaluation of zanubrutinib in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were intolerant to ibrutinib and/or acalabrutinib.

Bruce Haffty, MD, MS, discusses the feasibility of utilizing preoperative radiation boost in patients with breast cancer based on initial results from a phase 2 trial.

Asal Rahimi, MD, MS, discusses initial efficacy results from the expanded cohort of a phase 1 dose-escalation study (NCT04040569) evaluating pre-operative, single fraction stereotactic ablative radiation in early-stage, hormone receptor–positive breast cancer.

Melissa O'Neil, MRT(T), discusses findings from the randomized phase 2 Diagnostic CT-Enabled Radiation Therapy trial of palliative radiation therapy.

Julia S. Wong, MD, discusses findings from data presented on patient-reported toxicity results from the randomized trial of fractionation following breast reconstruction in patients with breast cancer.

Matthew Pierre Deek, MD, discusses the significance of pretreatment immune cell infiltration in patients with muscle-invasive bladder cancer who had been treated with definitive chemoradiation.

Bradford (Brad) S. Hoppe, MD, MPH, discusses the rationale for investigating consolidative radiotherapy in place of autologous stem cell transplant in patients with low-risk, relapsed/refractory classic Hodgkin lymphoma who have been previously treated with nivolumab plus brentuximab vedotin, as investigated in the phase 2 CheckMate 744 study, as well as key findings from this trial.

Michael Chuong, MD, FACRO, discusses patterns of locoregional recurrence following guided radiation therapy in pancreatic cancer.

Jiye Liu, PhD, discusses epigenetic regulation of CD38/CD48 in multiple myeloma.